Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vascular and Renal Impact of Endothelin-1 Receptor Blockade in Resistant Arterial Hypertension
2019-002334-36Phase 2Active
- Sponsor
- Rouen University Hospital
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of bosentan in arterial hypertension (HTN), sponsored by Rouen University Hospital. Primary endpoint: Endothelium-dependent radial artery dilatation change at 8 weeks. Started Aug 2019; status: active.
02
Drugs
bosentan
03
Conditions
arterial hypertension (HTN)
Beyond the preview
Go deeper on 2019-002334-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002334-36.